...
首页> 外文期刊>Pediatric nephrology: journal of the International Pediatric Nephrology Association >Treatment of autosomal dominant polycystic kidney disease (ADPKD): the new horizon for children with ADPKD.
【24h】

Treatment of autosomal dominant polycystic kidney disease (ADPKD): the new horizon for children with ADPKD.

机译:常染色体显性遗传性多囊肾疾病(ADPKD)的治疗:ADPKD儿童的新视野。

获取原文
获取原文并翻译 | 示例

摘要

Polycystic kidney disease (PKD) is the most common inherited renal disorder. Patients with PKD remain clinically asymptomatic for decades, while significant anatomic and physiologic systemic changes take place. Sequencing of the responsible genes and identification of their protein products have significantly expanded our understanding of the pathophysiology of PKD. The molecular basis for cystogenesis is being unraveled, leading to new targets for therapy and giving hope to millions of people suffering from PKD. This has direct implications for children with PKD with regard to screening for the disease and identification of high-risk individuals. In this article we provide a review of the clinical manifestations in children with autosomal dominant polycystic kidney disease (ADPKD), the genetic and molecular basis for the disease, and a concise review of potential therapies being evaluated.
机译:多囊肾病(PKD)是最常见的遗传性肾脏疾病。 PKD患者数十年来一直无临床症状,同时发生了明显的解剖和生理系统性变化。负责任基因的测序及其蛋白产物的鉴定已大大扩展了我们对PKD病理生理学的理解。囊肿发生的分子基础尚未阐明,导致了新的治疗靶标,并给数百万患有PKD的人们带来了希望。这对于PKD患儿筛查疾病和鉴定高危个体具有直接影响。在本文中,我们对常染色体显性遗传性多囊肾病(ADPKD)儿童的临床表现,疾病的遗传和分子基础进行了综述,并对正在评估的潜在疗法进行了简要综述。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号